3SBio Chief Financial Officer Tony He announced plans for additional business development deals as the Chinese biopharmaceutical company capitalizes on its recent momentum. Speaking from the JPMorgan Healthcare Conference in San Francisco, He expressed confidence in the firm's strategic direction. The company is actively seeking new partnerships to expand its global footprint and product pipeline.

He discussed the progress of 3SBio's landmark licensing agreement with Pfizer, struck last year. This record deal serves as a cornerstone for the company's international ambitions and validates its research capabilities. Such collaborations are vital for Chinese firms seeking to break into Western markets, providing capital and regulatory expertise while offering multinationals access to innovative assets.

Looking ahead, He indicated that 3SBio is evaluating multiple opportunities to build on its recent success. The CFO's comments from the 'Bloomberg: The China Show' signal a busy period for the firm's dealmaking team. Investors will watch for announcements that could further solidify 3SBio's position in the competitive biotech sector.